Formyl peptide receptor links inflammation to lung disease in rheumatoid arthritis
Official title: Formyl peptide receptor-mediated inflammation and pulmonary fibrosis
Funded at University of Washington · NIH-11451453 · Data updated 2026-11-12
This grant looks at how a receptor on immune cells may drive lung inflammation in people with rheumatoid arthritis and related conditions.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 11, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $264,750 |
| NIH project number | 1R21AI196947-01A1 |
| Project ID | NIH-11451453 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with rheumatoid arthritis, with or without interstitial lung disease, and healthy controls.
✕Less likely to help
Healthy individuals without inflammatory diseases are unlikely to benefit directly.
What this research studies
Neutrophils are early responders in our immune system, and a receptor called FPR1 may guide them to sites of tissue injury. The study will examine how N-formyl methionine peptides activate FPR1 in people with RA and RA-ILD, a lung complication that can be serious. Using patient samples like plasma and sputum, researchers will measure peptide signals and neutrophil activity to understand how this pathway contributes to lung inflammation. The goal is to identify mechanisms that could be targeted to reduce tissue damage and improve outcomes for patients affected by RA and RA-ILD.
Why it matters
Potential benefit: If successful, this work could reveal targets to dampen harmful neutrophil-driven inflammation in RA-ILD, potentially slowing lung damage.
How similar studies have gone: Prior research has linked neutrophil activation and FPR1 signaling to inflammatory diseases, suggesting this area is promising but still exploratory.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Lood, Jan Christian — University of Washington
- Study coordinator: Lood, Jan Christian
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.